Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 2015. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibilities (PDMR), and Connected Persons under the GlaxoSmithKline 2009 Performance Share Plan.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the valuation of share plan transactions:
- Ordinary Share Price: 1,611.00 pence per share.
- ADS Price: $47.72 per American Depositary Share.
- Transaction Type: Notional increases in share interests following the re-investment of dividends paid on April 9, 2015.
Material Changes
The filing details specific increases in notional shareholdings for various executives and connected persons. No material changes to the company's overall financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. It strictly reports compliance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c) regarding insider transactions.
Key Facts for Investor Verification
- Verify the vesting conditions and measurement periods for the 2009 Performance Share Plan to understand when notional dividends will be paid out.
- Confirm the total aggregate value of notional increases for all listed Directors and PDMRs against the reported share prices.
- Note that this filing is a regulatory disclosure of insider activity and does not reflect the company's quarterly or annual financial performance.